Ilofotase alfa
Highest phase reached
Phase 2
Drug type
Enzyme
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Enzyme
- Drug name
- Ilofotase alfa
- -365-INTESTINAL ALKALINE PHOSPHATASE (279-LEUCINE,328-VALINE) (HUMAN) FUSION PROTEIN WITH 366-430-PLACENTAL ALKALINE PHOSPHATASE (HUMAN) FUSION PROTEIN WITH 431-484-INTESTINAL ALKALINE PHOSPHATASE (478-LEUCINE) (HUMAN), DIMER
- 365 intestinal alkaline phosphatase 279 leucine 328 valine human fusion protein with 366 430 placental alkaline phosphatase human fusion protein with 431 484 intestinal alkaline phosphatase 478 leucine human dimer
- CHIMERIC HUMAN ALKALINE PHOSPHATASE (HUMAN INTESTINAL ALKALINE PHOSPHATASE (HIAP) CATALYTIC DOMAIN AND THE HUMAN PLACENTAL ALKALINE PHOSPHATASE (HPLAP) CROWN DOMAIN THAT LACKS THE GLYCOSYLPHOSPHATIDYLINOSITOL (GPI) ANCHOR OF HIAP)
- chimeric human alkaline phosphatase human intestinal alkaline phosphatase hiap catalytic domain and the human placental alkaline phosphatase hplap crown domain that lacks the glycosylphosphatidylinositol gpi anchor of hiap
- human intestinal type alkaline phosphatase iap variant h279 l l328 v p478 l engineered by substituting its crown domain 366 430 with the human placental type alkaline phosphatase placental alkaline phosphatase 1 plap 1 crown domain 364 428 366 430 in the current sequence c terminal linked glycosylphosphatidylinositol anchor removed dimer glycosylated produced in chinese hamster ovary cho cells human intestinal type alkaline phosphatase alpi intestinal alkaline phosphatase iap variant h279 l l328 v p478 l 1 484 with its crown domain 65 peptide 366 430 being replaced by the human placental type alkaline phosphatase alpp alkaline phosphatase regan isozyme placental alkaline phosphatase 1 plap 1 crown domain 65 peptide 364 428 366 430 dimer 481 481 disulfide without glycosylphosphatidylinositol gpi anchors at asp 484 and asp 484 secretable soluble enzyme produced in chinese hamster ovary cho cells glycoform alfa
- HUMAN INTESTINAL-TYPE ALKALINE PHOSPHATASE (IAP) VARIANT (H279>L, L328>V, P478>L), ENGINEERED BY SUBSTITUTING ITS CROWN DOMAIN (366-430) WITH THE HUMAN PLACENTAL-TYPE ALKALINE PHOSPHATASE (PLACENTAL ALKALINE PHOSPHATASE 1, PLAP-1) CROWN DOMAIN (364-428, 366-430 IN THE CURRENT SEQUENCE), C-TERMINAL LINKED GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR REMOVED, DIMER, GLYCOSYLATED, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS; HUMAN INTESTINAL-TYPE ALKALINE PHOSPHATASE (ALPI, INTESTINAL ALKALINE PHOSPHATASE, IAP) VARIANT (H279>L, L328>V, P478>L) (1-484) WITH ITS CROWN DOMAIN (65-PEPTIDE 366-430) BEING REPLACED BY THE HUMAN PLACENTAL-TYPE ALKALINE PHOSPHATASE (ALPP, ALKALINE PHOSPHATASE REGAN ISOZYME, PLACENTAL ALKALINE PHOSPHATASE 1, PLAP-1) CROWN DOMAIN (65-PEPTIDE 364-428) (366-430), DIMER (481-481')-DISULFIDE, WITHOUT GLYCOSYLPHOSPHATIDYLINOSITOL (GPI) ANCHORS AT ASP-484 AND ASP-484' (SECRETABLE, SOLUBLE ENZYME), PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA
- human recap
- human recAP
- Human recap
- iap
- IAP
- ilofotase alfa
- Ilofotase alfa
- ilofotase alfa [INN]
- ILOFOTASE ALFA [USAN]
- ilofotase alfa inn
- ilofotase alfa usan
- recap
- Recap
- RECOMBINANT HUMAN ALKALINE PHOSPHATASE (HUMAN INTESTINAL (ALPI), PLACENTAL (ALPP) CHIMERIC PROTEIN)
- recombinant human alkaline phosphatase human intestinal alpi placental alpp chimeric protein
- CAS registry numbers
- 2387636-92-0
- ChEMBL ID
- CHEMBL4594490
- FDA ingredient codes (UNII)
- 9N4Y2R43OM
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -ase
- Condition
- Acute Kidney Injury
- Highest recorded phase
- 2
- Condition identifier
- HP:0001919
- Subject identifier
- D058186
- Condition
- Acute Kidney Injury
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002492
- Subject identifier
- D058186
- Condition identifier
- EFO_0004352
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002492
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002492
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 0
- Condition identifier
- MONDO_0018570
- Highest recorded phase
- 1
Trial references
- NCT02182440
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 122 $ 122'' $ 249 $ 249''
- Component
- Sequence (X, X')
- Type
- Protein
- Sequence
- VIPAEEENPAFWNRQAAEALDAAKKLQPIQKVAKNLILFLGDGLGVPTVTATRILKGQKNGKLGPETPLAMDRFPYLALSKTYNVDRQVPDSAATATAYLCGVKANFQTIGLSAAARFNQCNTTRGNEVISVMNRAKQAGKSVGVVTTTRVQHASPAGTYAHTVNRNWYSDADMPASARQEGCQDIATQLISNMDIDVILGGGRKYMFPMGTPDPEYPADASQNGIRLDGKNLVQEWLAKHQGAWYVWNRTELMQASLDQSVTHLMGLFEPGDTKYEILRDPTLDPSLMEMTEAALRLLSRNPRGFYLFVEGGRIDHGHHEGVAYQAVTEAVMFDDAIERAGQLTSEEDTLTLVTADHSHVFSFGGYPLRGSSIFGLAPGKARDRKAYTVLLYGNGPGYVLKDGARPDVTESESGSPEYRQQSAVPLDEETHGGEDVAVFARGPQAHLVHGVQEQSFVAHVMAFAACLEPYTACDLALPACTTD
- Component
- Glycosylation sites (N)
- Sequence
- 122 $ 122' $ 249 $ 249'
- Component
- Disulfide bridges
- Sequence
- 121-183 $ 121'-183' $ 467-484 $ 467'-484' $ 481-481'
Related records
Trials (5)
- A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
- Effect of Intrapartum Antibiotic Prophylaxis (IAP) on the Development of the Neonatal Gut Microbiota.
- Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery
- Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
- Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects
In development for (1)
- Acute kidney injury Phase 2